Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
- Sanwa Kagaku, DSP to Terminate Copromotion Deal for Seibule
September 24, 2013
- Sanofi K.K. Launches GLP-1 Receptor Agonist Lyxumia
September 20, 2013
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
- Ethical Drug Sales Up 5.7% in July: Crecon Report
September 20, 2013
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
- Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
- Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval
September 18, 2013
- Takeda Grants Arbor Exclusive Rights for Edarbi Family of Products in US
September 17, 2013
- Xalkori Significantly Extends PFS in Japanese Patients: Pfizer
September 17, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…